PO-1058: Maintenance BEZ235 following BEZ235 and radiation prolongs therapeutic effect in colorectal cancer
نویسندگان
چکیده
منابع مشابه
NVP-BEZ235 as a new therapeutic option for sarcomas.
PURPOSE To evaluate the in vitro and in vivo effects of NVP-BEZ235, a dual pan-phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor in the three most common musculoskeletal tumors (osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma). EXPERIMENTAL DESIGN Antiproliferative activity as well as the effects on migration and metastasis were evaluated in a panel of osteosarcoma, Ewing'...
متن کاملPI3K and mTOR inhibitor, NVP-BEZ235, is more toxic than X-rays in prostate cancer cells
Background: Radiotherapy and adjuvant androgen deprivation therapy have historically been the first treatment choices for prostate cancer but treatment resistance often limits the capacity to effectively manage the disease. Therefore, alternative therapeutic approaches are needed. Here, the efficacies of radiotherapy and targeting the pro-survival cell signaling components epidermal growth fact...
متن کاملNVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma
Osteosarcoma(OS) remains a major health concern in childhood and adolescence, although cisplatin is one of the gold standard chemotherapeutic drugs in the treatment of OS, chemoresistant to cisplatin is common. Phosphoinositide 3-kinase (PI3K)-Akt-mammalian target of rapamycin inhibitor (mTOR) pathway and autophagy regulates chemosensitivity incancer cells. In this study, we hypothesized that N...
متن کاملBEZ235: When Promising Science Meets Clinical Reality
In the July 2016 issue of The Oncologist, Carlo et al. report the results of a phase I clinical trial [1] of BEZ235 in patients with advancedrenal cell carcinoma(RCC).BEZ235 isadualpan-class PI3K and mTOR inhibitor currently undergoing phase I/II clinical trials as a single agent or in combination in solid tumors and hematologic malignancies. The authors are to be congratulated for reportingthe...
متن کاملBEZ235 impairs gastric cancer growth by inhibition of PI3K/mTOR in vitro and in vivo
Background Gastric cancer at advanced stage of disease is a major health problem and the prognosis with the current therapeutic treatment strategies remains poor. PI3K/mTOR pathway mutations, especially PTEN, PI3K3C and AKT mutations and pS6 overexpression, are found frequently in gastric cancer patients and are linked with poor outcome. Thus, we evaluated the dual PI3K and mTOR inhibitor BEZ23...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Radiotherapy and Oncology
سال: 2018
ISSN: 0167-8140
DOI: 10.1016/s0167-8140(18)31368-9